Tower Research Capital LLC TRC Has $451,000 Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

Tower Research Capital LLC TRC increased its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 308.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 61,391 shares of the company's stock after purchasing an additional 46,378 shares during the period. Tower Research Capital LLC TRC's holdings in Vir Biotechnology were worth $451,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Artisan Partners Limited Partnership acquired a new stake in shares of Vir Biotechnology during the 4th quarter worth approximately $6,742,000. Dimensional Fund Advisors LP grew its holdings in Vir Biotechnology by 58.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,915,465 shares of the company's stock worth $14,059,000 after purchasing an additional 703,360 shares during the period. Alta Partners Management Company L.P. acquired a new stake in Vir Biotechnology in the fourth quarter worth $3,593,000. Walleye Capital LLC increased its stake in Vir Biotechnology by 2,119.4% in the fourth quarter. Walleye Capital LLC now owns 434,460 shares of the company's stock valued at $3,189,000 after purchasing an additional 414,884 shares in the last quarter. Finally, abrdn plc acquired a new position in shares of Vir Biotechnology during the fourth quarter valued at about $2,666,000. 65.32% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director George A. Scangos sold 10,964 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total transaction of $107,556.84. Following the completion of the sale, the director now owns 708,295 shares in the company, valued at approximately $6,948,373.95. This trade represents a 1.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Backer Marianne De sold 79,712 shares of the business's stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total transaction of $474,286.40. Following the completion of the transaction, the chief executive officer now owns 769,505 shares in the company, valued at approximately $4,578,554.75. The trade was a 9.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 99,611 shares of company stock valued at $663,525 over the last three months. Corporate insiders own 15.60% of the company's stock.

Vir Biotechnology Trading Down 2.0 %

Shares of NASDAQ:VIR opened at $5.98 on Wednesday. The stock has a market cap of $825.62 million, a PE ratio of -1.53 and a beta of 1.14. The stock's fifty day simple moving average is $6.75 and its two-hundred day simple moving average is $8.04. Vir Biotechnology, Inc. has a 1-year low of $4.95 and a 1-year high of $14.45.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, beating analysts' consensus estimates of ($0.85) by $0.09. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The company had revenue of $12.37 million for the quarter, compared to analyst estimates of $8.14 million. On average, sell-side analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Morgan Stanley raised Vir Biotechnology from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $10.00 to $20.00 in a research report on Thursday, January 9th. Barclays boosted their price objective on Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a report on Friday, February 28th. JPMorgan Chase & Co. increased their target price on Vir Biotechnology from $10.00 to $14.00 and gave the stock a "neutral" rating in a report on Thursday, January 9th. Leerink Partners lifted their price target on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company an "outperform" rating in a research report on Monday, January 13th. Finally, The Goldman Sachs Group lowered their price objective on shares of Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $33.57.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).

Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.